M
M. Elizabeth Halloran
Researcher at Fred Hutchinson Cancer Research Center
Publications - 270
Citations - 19557
M. Elizabeth Halloran is an academic researcher from Fred Hutchinson Cancer Research Center. The author has contributed to research in topics: Vaccination & Population. The author has an hindex of 56, co-authored 248 publications receiving 15685 citations. Previous affiliations of M. Elizabeth Halloran include University of Washington & Washington University in St. Louis.
Papers
More filters
Journal ArticleDOI
Design of vaccine efficacy trials during public health emergencies
Natalie E. Dean,Pierre Stéphane Gsell,Ron Brookmeyer,Victor De Gruttola,Christl A. Donnelly,Christl A. Donnelly,M. Elizabeth Halloran,M. Elizabeth Halloran,Momodou Jasseh,Martha Nason,Ximena Riveros,Conall H. Watson,Ana Maria Henao-Restrepo,Ira M. Longini +13 more
TL;DR: The need for flexible and responsive vaccine trial designs to be used in public health emergencies is outlined, and recommendations for their use in this setting are summarized.
Journal ArticleDOI
Persistent Arthralgia Associated with Chikungunya Virus Outbreak, US Virgin Islands, December 2014-February 2016.
Leora R. Feldstein,Ali Rowhani-Rahbar,J. Erin Staples,Marcia R. Weaver,M. Elizabeth Halloran,Esther M. Ellis +5 more
TL;DR: After the 2014–2015 outbreak of chikungunya virus in the US Virgin Islands, the prevalence of persistent arthralgia was higher in case-patients than controls 6 and 12 months after disease onset.
Journal ArticleDOI
Projected Impact of Dengue Vaccination in Yucatán, Mexico
Thomas J. Hladish,Carl A. B. Pearson,Dennis L. Chao,Diana Patricia Rojas,Gabriel Recchia,Héctor Gómez-Dantés,M. Elizabeth Halloran,M. Elizabeth Halloran,Juliet R. C. Pulliam,Ira M. Longini +9 more
TL;DR: It is found that plausible vaccination scenarios with a durable vaccine reduce annual dengue incidence by as much as 80% within five years, however, if vaccine efficacy wanes after administration, there can be years with larger epidemics than would occur without any vaccination, and that vaccine booster doses are necessary to prevent this outcome.
Journal ArticleDOI
Rotavirus vaccine effectiveness in low-income settings: An evaluation of the test-negative design.
TL;DR: The test-negative design (TND) is an appropriate method to measure RV effectiveness in low-income settings and was evaluated using randomized trials of RV in sub-Saharan Africa and Asia.
Journal ArticleDOI
Using Validation Sets for Outcomes and Exposure to Infection in Vaccine Field Studies
TL;DR: In this paper, the authors show how use of small validation sets can correct the bias of the estimates obtained from a large main study while maintaining efficiency.